Evidence map›Paper›PMID 26841902›Full record

Trial reportInvestigational new drugs2016

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.

Elaine McWhirter, Ian Quirt, Thomas Gajewski, Gregory Pond, Lisa Wang, June Hui, Amit Oza

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Investigational new drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elaine McWhirterDepartment of Medical Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, Hamilton, ON, Canada. emcwhirt@hhsc.ca.
Ian QuirtDepartment of Medical Oncology, Princess Margaret Cancer Centre, Drug Development Program, Toronto, ON, Canada.
Thomas GajewskiUniversity of Chicago Medical Centre, Chicago, IL, USA.
Gregory PondOntario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada.
Lisa WangDepartment of Medical Oncology, Princess Margaret Cancer Centre, Drug Development Program, Toronto, ON, Canada.
June HuiDepartment of Medical Oncology, Princess Margaret Cancer Centre, Drug Development Program, Toronto, ON, Canada.
Amit OzaDepartment of Medical Oncology, Princess Margaret Cancer Centre, Drug Development Program, Toronto, ON, Canada.

Funding

PHS HHS HHSN261201100032C
6 · The paper itself

Abstract

purposeA two stage multi-institution Phase II study was undertaken by the Princess Margaret Hospital Consortium to evaluate the efficacy and toxicity of oral cediranib, an inhibitor of vascular endothelial growth factor receptors 1 and 2, in patients with previously untreated advanced malignant melanoma. PATIENTS AND

methodsBetween May 2006 and April 2008, 24 patients (median age 65 years) with advanced malignant melanoma were treated with oral cediranib. Cediranib was given on a continuous, oral once daily schedule of 45 mg, on a 28 day cycle.

resultsOf the 17 patients evaluable for response, there was stable disease in 8 patients, and progressive disease in 9 patients, with no objective responses seen. Only 2 patients had stable disease >/= 6 months, thus the study was terminated at the end of stage 1 accrual. The overall median survival was 9.9 months, and the median time to progression was 3.5 months. The most frequent non-hematologic adverse events were hypertension (78%), fatigue (69%), diarrhea (69%) and anorexia and nausea (each 57%).

conclusionsAlthough 2 patients had stable disease at 6 months, the short median time to progression and lack of any objective responses indicate that single agent cediranib at this dose and schedule is not sufficiently active to warrant study continuation.

Indexed as

Administration, OralAdultAgedAged, 80 and overFemaleHumansIndolesMaleMelanomaMiddle AgedNeoplasm Recurrence, LocalQuinazolinesTreatment OutcomeVascular Endothelial Growth Factor AcediranibIndolesQuinazolinesVascular Endothelial Growth Factor ACediranibFirst line therapyMetastatic melanomaPhase II trialVascular endothelial growth factor (VEGF)

Identifiers

PMID26841902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.